The United Kingdom and the United States have agreed to a major trade agreement that will preserve no import taxes on UK medicine shipments entering the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to boost funding on drugs through the NHS. This pledge ensures that tariffs on these key products will be held at zero for a period of the next three years.
This development comes after previous threats to dramatically increase import taxes on branded pharmaceutical products, with increases discussed as high as double the cost.
"This arrangement with the United Kingdom bolsters the worldwide climate for innovative medicines and introduces long-overdue equity to transatlantic drug exports," an announcement said.
Trade Impact
Drugs are one of the UK's biggest export categories to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Export figures indicate that in the one-year period leading up to the third quarter, the UK exported medicines worth billions to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This deal secures work, stimulates funding and facilitates the UK to establish itself as a international leader for life sciences," a minister commented.
Specific UK Commitments
The agreement involves several specific commitments from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a target to raise overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%.
Industry Background
This agreement comes amid a ongoing tension between the sector and the UK government over medicine costs and regulatory access.
This friction were intensified by assertions that American customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been directed toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its resources over the previous ten-year period.
